# V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

> **NCT00378560** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1021 (actual)

## Conditions studied

- HPV Infections

## Interventions

- **BIOLOGICAL:** Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00378560
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-12
- **Primary completion:** 2009-09-16
- **Final completion:** 2009-09-16
- **Target enrollment:** 1021 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378560, "V501 Efficacy Study in Women Aged 18 to 26 (V501-027)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00378560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*